A phase I study of suramin with once- or twice-monthly dosing in patients with advanced cancer

[1]  F. Meyers,et al.  Suramin therapy for patients with symptomatic hormone-refractory prostate cancer: results of a randomized phase III trial comparing suramin plus hydrocortisone to placebo plus hydrocortisone. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  M. Ratain,et al.  Evaluation of neuropathy in patients on suramin treatment , 1997, Muscle & nerve.

[3]  L Janish,et al.  Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  D. Jodrell,et al.  Suramin: development of a population pharmacokinetic model and its use with intermittent short infusions to control plasma drug concentration in patients with prostate cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  W. Linehan,et al.  Effect of suramin on human prostate cancer cells in vitro. , 1991, The Journal of urology.

[6]  M. Dalakas,et al.  Suramin‐induced polyneuropathy , 1990, Neurology.